Keywords
HIV
Bone mass
Osteoporosis
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To analyze clinical and epidemiological aspects of low bone mass in menopausal women with HIV. Background: Antiretroviral therapy (ART) increased the life expectancy of people living with HIV (PLH), who are experiencing clinical issues of the elderly population. Many of these are women reaching the menopause/climacteric phase, which means an important challenge to clinicians, who are not well prepared to this complex management. In women living with HIV (WLH), hypoestrogenism resulting from ovarian failure joins to traditional risk factors and those related to HIV infection leading to low bone mass and potential risk of fractures. Evidence suggests periodic screening for low bone mass, calcium and vitamin D supplementation and the use of bisphosphonates for osteoporosis treatment. Final considerations: There are several data gaps regarding the relationship between HIV and the menopause, including the effect of hormone therapy (TH) on bone. It’s fundamental of clinicians to be aware of the full needs of WLH, that comprises much more than viral control, including a special management of bone mass.
References
ALVAREZ N, et al. The potential protective role of vitamin D supplementation on HIV-1 infection. Front Immunol., 2019; 10: 2291.
ALZAHRANI J, et al. Inflammatory and immunometabolic consequences of gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities. EBioMedicine, 2019; 46:522–31.
BIVER E, et al. Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis. Osteoporos Int., 2019; 30(5): 1125–1135.
BLACK DM, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res., 2015; 30: 934-944.
BOLLAND MJ, et al. Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men. J Clin Endocrinol Metab., 2012; 97(6): 1922–1928.
BONE HG et al; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med., 2004; 350: 1189-1199.
BRASIL. Ministério da Saúde. Banco de dados do Sistema Único de Saúde-DATASUS. Disponível em http://www.datasus.gov.br. Acessado em 30 de janeiro de 2023.
BROWN TT, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr., 2009; 51: 554–61.
CAULEY JA, et al. Women’s Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women’s Health Initiative randomized trial. JAMA, 2003; 290: 1729-1738.
CHANG CJ, et al. People with HIV infection had lower bone mineral density and increased fracture risk: a meta-analysis. Arch Osteoporos, 2021; 16(1): 47.
COMPSTON JE, et al. Osteoporosis. Lancet, 2019; 26(393): 364-376.
CORTÉS YI, et al. Bone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review. J Assoc Nurses AIDS Care, 2015; 26(4): 387-98.
COTTER AG e POWDERLY WG. Endocrine complications of human immunodeficiency virus infection: hypogonadism, bone disease and tenofovir-related toxicity. Best Res Clin End Metab., 2011; 25: 501–15.
DELPINO MV e QUARLERI J. Influence of HIV infection and antiretroviral therapy on bone homeostasis. Front Endocrinol., 2020; 11:502.
FARR JN e KHOSLA S. Skeletal changes through the lifespan—from growth to senescence. Nat Rev Endocrinol., 2015; 11: 513-521.
FINK HA, et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann Intern Med., 2019; 171: 37-50.
GIBELLINI D, et al. Analysis of the effects of specific protease inhibitors on OPG/RANKL regulation in an osteoblast-like cell line. New Microbiol., 2010; 33: 109–15.
GREENDALE GA, et al. Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women’s Health Across the Nation (SWAN). J Bone Miner Re., 2012; 27(1): 111–118.
GUARALDI G, et al. Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. PLoS ONE, 2015; 10: e0118531.
HANSEN D, et al. Medicare Cost of Osteoporotic Fractures: 2021 Updated Report: The Clinical and Cost Burden of Fractures Associated with Osteoporosis. National Osteoporosis Foundation, 2021.
HASKELBERG H, et al. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS ONE, 2012; 7: e38377.
HOSKING D, et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med., 1998; 338: 485-492.
HOWELLS P, et al. Experience of hormone replacement therapy in postmenopausal women living with HIV. Post Reprod Health., 2019; 25(2): 80-85.
IN DANGER: UNAIDS Global AIDS Update 2022. Joint United Nations Programme on HIV/AIDS; 2022.
KANIS JA et al. The diagnosis of osteoporosis. J Bone Miner Res., 1994; 9(8): 1137–114.
LeBOFF M, et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int., 2022; 33: 2049–2102.
LEWDEN C e BOUTELOUP V. All-cause mortality in treated HIV-infected adults with CD4 > 500/mm3 compared with the general population: Evidence from a large European observational cohort collaboration. Int J Epidemiol., 2012; 41: 433–445.
LOOKER AC, et al. Trends in osteoporosis and low bone mass in older US adults, 2005-2006 through 2013-2014. Osteoporos Int., 2017; 28: 1979 -1988.
LORENTZON M e CUMMINGS SR. Osteoporosis: the evolution of a diagnosis. J Intern Med., 2015; 277: 650–61.
MAZZITELLI M, et al. FRAX assessment in people ageing with HIV. HIV Med., 2022; 23(1): 103-108.
McCLUNG M, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med., 2013; 126: 13-20.
McCOMSEY GA, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis., 2010; 51(8): 937-46.
McCOMSEY GA et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis., 2011; 203: 1791–801.
NAMS. Management of Osteoporosis in Postmenopausal Women: The 2021 Position Statement of The North American Menopause Society’’ Editorial Panel. Management of osteoporosis in postmenopausal women: the 2021 position statement of The North American Menopause Society. Menopause, 2021; 28(9): 973-997.
NEGREDO E, et al. Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density: single dose versus two doses in 2 years. HIV Med., 2015; 16(7): 441–448.
NIH. Consensus development panel on osteoporosis prevention, diagnosis and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA, 2001; 285(6): 785-95.
OFOTOKUN I, et al. Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection. AIDS, 2016; 30: 405–14.
OVERTON ET, et al. Vitamin D and calcium attenuate bone loss with antiretroviral therapy initiation: a randomized trial. Ann Intern Med., 2015; 162(12): 815–824.
PAPADAKIS G, et al. The benefit of menopausal hormone therapy on bone density and microarchitecture persists after its withdrawal. J Clin Endocrinol Metab., 2016; 101: 5004- 5011.
PETERS BS, et al. Prevalence of vitamin D insufciency in Brazilian adolescents. Ann Nutr Metab., 2009; 54: 15–21.
PRAMUKTI I, et al. Bone fracture among people living with HIV: a systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS ONE, 2020; 15(6): e0233501.
PRIOR J, et al. Fragility fractures and bone mineral density in HIV positive women: a case-control population-based study. Osteoporos Int., 2007; 18(10): 1345-53.
SALARI N, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res., 2021; 16(1): 609.
SALARI N, et al. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res., 2021; 16(1): 669.
SCHUIT SC, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone, 2004; 34: 195–202.
SHIAU S, et al. Bone Update: Is It Still an Issue Without Tenofovir Disoproxil Fumarate? Curr HIV/AIDS Rep., 2020; 17(1): 1-5.
STARUP-LINDE J, et al. Management of osteoporosis in patients living with HIV-A systematic review and meta-analysis. J Acquir Immune Defc Syndr., 2020; 83(1): 1–8.
VANCE DE, et al. Successful aging and the epidemiology of HIV. Clin Interv Aging, 2011; 6: 181–192.
WANG H, et al. The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: metaanalysis. Medicine, 2016; 95: e5146.
YIN MT e FALUTZ J. How to predict the risk of fracture in HIV? Curr Opin HIV AIDS, 2016; 11(3): 261-7.
YIN MT, et al. Hormone therapy and fractures in postmenopausal women. AIDS, 2022; 36(12): 1683-1688.
YIN MT, et al. A Randomized Placebo-Controlled Trial of Low- Versus Moderate-Dose Vitamin D3 Supplementation on Bone Mineral Density in Postmenopausal Women With HIV. J Acquir Immune Defic Syndr., 2019; 80(3): 342-349.